Europe Epigenetics Market Size, Share, Manufacturers, Countries and Forecasts To 2024

The European epigenetics market is expected to register a CAGR of nearly 14.5% over the forecast period. Factors that are responsible for the growth of this market include the increasing incidence and prevalence of cancer, the increased funding for R&D in healthcare, and rising epigenetic applications in non-oncology diseases.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/19833
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

The epigenetics market is increasing in the European region. For instance, according to WHO, more than 3.7 million new cases of cancer and 1.9 million deaths occur due to cancer every year, and cancer represents the second most important cause of death and morbidity in the European region. Epigenetics is used in the study of changes in gene expression, which are useful in cancer diagnosis. This depicts the large patient pool of cancer patients, which will propel the growth of the epigenetics market. So, with the increasing cancer prevalence, the market is expected to grow. However, factors, such as the rising cost of instruments are expected to restrain the growth of the market.

Top Players:
The European epigenetic market is moderately competitive and consists of several major players. In terms of market share, a few of the major players currently dominate the market. With the rising need for mobile health and the advances in ultrasonography, a few smaller players are entering the market and holding a substantial share. Some of the major players of the market are Merck & Co., Qiagen, Roche, Thermo Fisher Scientific, and Illumina Inc., among others.

Request Discount on this report @ https://marketprognosis.com/discount-request/19833
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Scope of the Report
Epigenetics is defined as the study of changes in gene expression, which are caused by certain base pairs in DNA, or RNA, being turned off or on again, through the chemical reactions.

Oncology is Expected to Grow Faster in the Application Segment
In the last few years, the market has been a golden age for cancer genetics. The cost of gene sequencing has dropped low enough for researchers to read the genomes of many thousands of patients, comparing the DNA of the diseased and healthy tissues to find the mutations associated with tumor formation and growth, which is associated with cancer. The epigenetic innovations are unobtrusively crafting a toolbox for the powerful drugs to treat cancer. And the rising prevalence of cancer in the European region is expected to drive the oncology application in the European epigenetic market.

Enquiry Before Buying @ https://marketprognosis.com/enquiry/19833

Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.